AavantiBio, Inc.

Please note: The information displayed on this page might be outdated.
AavantiBio, Inc.: AavantiBio is a clinical stage gene therapy company backed by a premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management, who led the company’s recent $107 million Series A financing. Headquartered in the greater Boston area, AavantiBio is pursuing a diversified gene therapy pipeline, including a lead program in Friedreich’s Ataxia (FA), a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company benefits from strategic partnerships with the University of Florida’s renowned Powell Gene Therapy Center and the MDA Care Center at UF Health where AavantiBio’s co-founders and renowned gene therapy researchers Barry Byrne, M.D., Ph.D. and Manuela Corti, P.T., Ph.D maintain their research and clinical practices.
Sector/Industry:
Healthcare
Characteristics:
Based in...
US - New England
Listing
Private
Website:
Profiles:
Address:
245 First Street, Riverview II
18th Floor
Cambridge, MA 02142
United States

Company Participants at Spring Private Company Showcase

Bo Cumbo
AavantiBio, Inc., CEO
Alexander “Bo” Cumbo, a seasoned biopharmaceutical executive, has been appointed AavantiBio’s Chief Executive Officer and President, effective immediately. Mr. Cumbo joins the Company after eight years at Sarepta, where he served as Chief Commercial Officer and Executive Vice President. He will continue to serve as an advisor to Sarepta through December 31, 2020. Prior to joining Sarepta in 2013, Mr. Cumbo served as Vice President of Sales and Treatment Education at Vertex Pharmaceuticals where he built a sales force to market their first commercial drug, Incivek—an oral treatment for hepatitis C. Previously, he spent nine years at Gilead Sciences where he served in multiple commercial roles supporting the company’s HIV, HBV, and cardiovascular franchises. Mr. Cumbo has extensive experience building global commercial infrastructure, and throughout his career, he has contributed to the launch of 11 specialty products across multiple organizations. He received his Bachelor of Science in Laboratory Technology from Auburn University.
Doug Swirsky
AavantiBio, Inc., Chief Financial Officer
Senior executive with over twenty-five years of experience including fourteen years of public company C-level service. Focused on the financial, strategic and operational aspects of biotechnology, experience also includes nine years in investment banking and four years in public accounting and consulting. Accomplished in securing, structuring and negotiating financing transactions. Significant experience working with and serving on boards of directors of public companies. Demonstrated ability to understand and communicate scientific concepts.